Variable Impact on Mortality of AIDS‐Defining Events Diagnosed during Combination Antiretroviral Therapy: Not All AIDS‐Defining Conditions Are Created Equal
Open Access
- 15 April 2009
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 48 (8), 1138-1151
- https://doi.org/10.1086/597468
Abstract
Background. The extent to which mortality differs following individual acquired immunodeficiency syndrome (AIDS)-defining events (ADEs) has not been assessed among patients initiating combination antiretroviral therapy. Methods. We analyzed data from 31,620 patients with no prior ADEs who started combination antiretroviral therapy. Cox proportional hazards models were used to estimate mortality hazard ratios for each ADE that occurred in >50 patients, after stratification by cohort and adjustment for sex, HIV transmission group, number of antiretroviral drugs initiated, regimen, age, date of starting combination antiretroviral therapy, and CD4+ cell count and HIV RNA load at initiation of combination antiretroviral therapy. ADEs that occurred in Results. During a median follow-up period of 43 months (interquartile range, 19–70 months), 2880 ADEs were diagnosed in 2262 patients; 1146 patients died. The most common ADEs were esophageal candidiasis (in 360 patients), Pneumocystis jiroveci pneumonia (320 patients), and Kaposi sarcoma (308 patients). The greatest mortality hazard ratio was associated with non-Hodgkin' lymphoma (hazard ratio, 17.59; 95% confidence interval, 13.84–22.35) and progressive multifocal leukoencephalopathy (hazard ratio, 10.0; 95% confidence interval, 6.70–14.92). Three groups of ADEs were identified on the basis of the ranked hazard ratios with bootstrapped confidence intervals: severe (non-Hodgkin' lymphoma and progressive multifocal leukoencephalopathy [hazard ratio, 7.26; 95% confidence interval, 5.55–9.48]), moderate (cryptococcosis, cerebral toxoplasmosis, AIDS dementia complex, disseminated Mycobacterium avium complex, and rare ADEs [hazard ratio, 2.35; 95% confidence interval, 1.76–3.13]), and mild (all other ADEs [hazard ratio, 1.47; 95% confidence interval, 1.08–2.00]). Conclusions. In the combination antiretroviral therapy era, mortality rates subsequent to an ADE depend on the specific diagnosis. The proposed classification of ADEs may be useful in clinical end point trials, prognostic studies, and patient management.Keywords
This publication has 33 references indexed in Scilit:
- Efficacy and Safety of Emtricitabine vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA Randomized TrialPublished by American Medical Association (AMA) ,2004
- Combination Antiretroviral Therapy and the Risk of Myocardial InfarctionNew England Journal of Medicine, 2003
- Composite Outcomes in Randomized TrialsJAMA, 2003
- Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studiesThe Lancet, 2002
- CD4 Count and the Risk for Death in Patients Infected with HIV Receiving Antiretroviral TherapyAnnals of Internal Medicine, 1991
- The AIDS-defining diagnosis and subsequent complications: a survival-based severity index.1991
- Leads from the MMWR. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome.1987
- Revision of the case definition of acquired immunodeficiency syndrome for national reporting--United States. Centers for Disease Control, Department of Health and Human Services.1985
- Pneumocystis cariniiPneumonia and Mucosal Candidiasis in Previously Healthy Homosexual MenNew England Journal of Medicine, 1981
- KAPOSI'S SARCOMA IN HOMOSEXUAL MEN—A REPORT OF EIGHT CASESThe Lancet, 1981